Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)
Abstract Background There is limited evidence over the real‐life secukinumab survival in psoriatic patients, especially in the long‐term bio‐naïve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that early...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.185 |
| _version_ | 1797729096696856576 |
|---|---|
| author | Francisco Javier Melgosa Ramos Almudena Mateu Puchades Santiago Guillén Climent Marta Galarreta Pascual Marina Saéz Belló María Angels Martínez Ferrer Fernando Toledo Alberola Jorge Magdaleno Tapial Jose Luís Sánchez Carazo Javier Matáix Díaz Luca Schneller‐Pavelescu Apetrei Laura García Fernández Iris González Villanueva Isabel Belinchón Romero Sergio Martín Jiménez Sergio Santos Alarcón |
| author_facet | Francisco Javier Melgosa Ramos Almudena Mateu Puchades Santiago Guillén Climent Marta Galarreta Pascual Marina Saéz Belló María Angels Martínez Ferrer Fernando Toledo Alberola Jorge Magdaleno Tapial Jose Luís Sánchez Carazo Javier Matáix Díaz Luca Schneller‐Pavelescu Apetrei Laura García Fernández Iris González Villanueva Isabel Belinchón Romero Sergio Martín Jiménez Sergio Santos Alarcón |
| author_sort | Francisco Javier Melgosa Ramos |
| collection | DOAJ |
| description | Abstract Background There is limited evidence over the real‐life secukinumab survival in psoriatic patients, especially in the long‐term bio‐naïve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that early intensive treatment with biological therapies could decrease pathogenic tissue resident memory (TRm) cells migration and potentially modify the natural course of psoriasis and related comorbidities. Objectives To analyze long‐term secukinumab efficacy, safety and survival, and its predictive factors for psoriasis treatment determining also whether early intervention may result in better outcomes for patients. Methods Bio‐naïve psoriatic patients under treatment with secukinumab (n = 128 patients) in a daily practice setting were analyzed in a retrospective multicentric study and followed up to 8 years. Drug survival rate, efficacy, posology and safety were reported. Results The overall secukinumab survival was 81.9% for an average treatment exposure of 147.9 weeks. The approved posology was the most commonly prescribed regimen (78.7%), and 17.7% could be optimized. An absolut‐PASI ≤3 was reached by 86.6%, 82.6% and 91.7% at the weeks 48,156 and 264, respectively. The incidence of arthritis or psoriasis related comorbidities was low. The response was not influenced by weight, age (>65), gender or the presence of arthritis. No severe adverse events were reported. Conclusions In our bio‐naïve series, the high efficacy and long‐term survival rates observed and the low prevalence of arthritis and comorbidities might suggest that early intervention could contribute to modify the course of the disease, but further studies are needed. |
| first_indexed | 2024-03-12T11:24:04Z |
| format | Article |
| id | doaj.art-57b2f2a64f8042c7a8bb1d22aed5f122 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-03-12T11:24:04Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-57b2f2a64f8042c7a8bb1d22aed5f1222023-09-01T12:30:54ZengWileyJEADV Clinical Practice2768-65662023-09-012357658210.1002/jvc2.185Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)Francisco Javier Melgosa Ramos0Almudena Mateu Puchades1Santiago Guillén Climent2Marta Galarreta Pascual3Marina Saéz Belló4María Angels Martínez Ferrer5Fernando Toledo Alberola6Jorge Magdaleno Tapial7Jose Luís Sánchez Carazo8Javier Matáix Díaz9Luca Schneller‐Pavelescu Apetrei10Laura García Fernández11Iris González Villanueva12Isabel Belinchón Romero13Sergio Martín Jiménez14Sergio Santos Alarcón15Department of Dermatology University Hospital Doctor Peset of Valencia Valencia SpainDepartment of Dermatology University Hospital Doctor Peset of Valencia Valencia SpainDepartment of Dermatology University Hospital Virgen de los Lirios Alcoy Alicante SpainDepartment of Dermatology University Hospital Doctor Peset of Valencia Valencia SpainDepartment of Dermatology University Hospital Doctor Peset of Valencia Valencia SpainDepartment of Rheumatology University Hospital Doctor Peset of Valencia Valencia SpainDepartment of Dermatology General University Hospital of Elche Alicante SpainDepartment of Dermatology General University Hospital of Valencia Valencia SpainDepartment of Dermatology General University Hospital of Valencia Valencia SpainDepartment of Dermatology Hospital Marina Alta, Vila‐Joyosa Alicante SpainDepartment of Dermatology Hospital de la Vega Baja Orihuela Alicante SpainDepartment of Dermatology University Hospital of San Juan Alicante SpainDepartment of Dermatology General University Hospital of Alicante Alicante SpainDepartment of Dermatology General University Hospital of Alicante Alicante SpainDepartment of Dermatology University Hospital Doctor Peset of Valencia Valencia SpainDepartment of Dermatology University Hospital Virgen de los Lirios Alcoy Alicante SpainAbstract Background There is limited evidence over the real‐life secukinumab survival in psoriatic patients, especially in the long‐term bio‐naïve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that early intensive treatment with biological therapies could decrease pathogenic tissue resident memory (TRm) cells migration and potentially modify the natural course of psoriasis and related comorbidities. Objectives To analyze long‐term secukinumab efficacy, safety and survival, and its predictive factors for psoriasis treatment determining also whether early intervention may result in better outcomes for patients. Methods Bio‐naïve psoriatic patients under treatment with secukinumab (n = 128 patients) in a daily practice setting were analyzed in a retrospective multicentric study and followed up to 8 years. Drug survival rate, efficacy, posology and safety were reported. Results The overall secukinumab survival was 81.9% for an average treatment exposure of 147.9 weeks. The approved posology was the most commonly prescribed regimen (78.7%), and 17.7% could be optimized. An absolut‐PASI ≤3 was reached by 86.6%, 82.6% and 91.7% at the weeks 48,156 and 264, respectively. The incidence of arthritis or psoriasis related comorbidities was low. The response was not influenced by weight, age (>65), gender or the presence of arthritis. No severe adverse events were reported. Conclusions In our bio‐naïve series, the high efficacy and long‐term survival rates observed and the low prevalence of arthritis and comorbidities might suggest that early intervention could contribute to modify the course of the disease, but further studies are needed.https://doi.org/10.1002/jvc2.185bio‐naïveIL‐17 inhibitorspsoriasisreal‐world experiencesecukinumab |
| spellingShingle | Francisco Javier Melgosa Ramos Almudena Mateu Puchades Santiago Guillén Climent Marta Galarreta Pascual Marina Saéz Belló María Angels Martínez Ferrer Fernando Toledo Alberola Jorge Magdaleno Tapial Jose Luís Sánchez Carazo Javier Matáix Díaz Luca Schneller‐Pavelescu Apetrei Laura García Fernández Iris González Villanueva Isabel Belinchón Romero Sergio Martín Jiménez Sergio Santos Alarcón Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients) JEADV Clinical Practice bio‐naïve IL‐17 inhibitors psoriasis real‐world experience secukinumab |
| title | Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients) |
| title_full | Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients) |
| title_fullStr | Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients) |
| title_full_unstemmed | Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients) |
| title_short | Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients) |
| title_sort | long term secukinumab efficacy and safety in bio naive patients with moderate to severe cutaneous psoriasis a real world retrospective noninterventional multicentric experience 128 patients |
| topic | bio‐naïve IL‐17 inhibitors psoriasis real‐world experience secukinumab |
| url | https://doi.org/10.1002/jvc2.185 |
| work_keys_str_mv | AT franciscojaviermelgosaramos longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT almudenamateupuchades longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT santiagoguillencliment longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT martagalarretapascual longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT marinasaezbello longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT mariaangelsmartinezferrer longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT fernandotoledoalberola longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT jorgemagdalenotapial longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT joseluissanchezcarazo longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT javiermataixdiaz longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT lucaschnellerpavelescuapetrei longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT lauragarciafernandez longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT irisgonzalezvillanueva longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT isabelbelinchonromero longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT sergiomartinjimenez longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients AT sergiosantosalarcon longtermsecukinumabefficacyandsafetyinbionaivepatientswithmoderatetoseverecutaneouspsoriasisarealworldretrospectivenoninterventionalmulticentricexperience128patients |